Royalty Pharma drops hostile bid for Elan

US-based investor withdraws request for judicial review of Takeover Panel’s decision requiring it to lapse Elan offer

Elan loses shareholder support but Royalty bid may also perish

Outcome of special meeting in Dublin leaves sides effectively in stalemate

Elan shareholders mull the unravelling of a business

How the Irish biotech firm got to this point and how the EGM may play out

Cantillon: Elan paying the price of misplaying its hand

Royalty gets injunction in challenge to Takeover Panel on Elan bid

Court move means bid will not lapse pending full hearing even if shareholders back certain resolutions

Royalty looks to fast-track challenge to Takeover Panel ruling

Fund seeks stay on decision regarding $6.7bn Elan bid until Commercial Court rules

Royalty Pharma challenges ruling that it must withdraw Elan bid

Deadline looms for vote of proxies in bitter battle

Cantillon: Royalty’s latest bid could prove a bitter pill to swallow for Elan

Elan drops Royalty Pharma injunction as Takeover Panel steps in

Bid target says suitor agrees to hold back on proxy statement to shareholders

Royalty Pharma given May deadline to make firm offer for Elan

Takeover Panel sets deadline for $6.6bn ‘indicative’ bid